根据最新的SEC文件显示，目前股价为71.62美元、市值420亿美元的医疗设备公司Edwards Lifesciences Corp (NYSE: EW )的首席财务官Scott B. Ullem于2025年2月28日进行了重要的股票交易。根据 InvestingPro ...

Sigma Planning Corp reduced its stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...

Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.